Search - tctmd.com

Displaying 1 - 20 of 146

Sort: Relevancy | Date

Top News in Coronary Artery Disease: 2018

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

News Daily News

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

December 11, 2018

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

December 07, 2018

US and European DAPT Guidelines More Alike Than Different, Say Experts

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

News Daily News

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

November 28, 2018

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

News Daily News

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

November 20, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

New-Generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

News Conference News AHA 2018

New-Generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

November 12, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Conference News VIVA 2018

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

November 08, 2018

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

November 06, 2018

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

TCTMD’s Top 10 Most Popular Stories for October 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

October 31, 2018

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

News Daily News

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

October 26, 2018

Automated Email Reminders May Boost IVC Filter Retrieval, Cut Complications

News Daily News

Automated Email Reminders May Boost IVC Filter Retrieval, Cut Complications

October 23, 2018

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

News Daily News

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

Michael O'Riordan

October 19, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

Patients With A-fib and Cancer May Benefit From Visiting With a Cardiologist Early On

News Daily News

Patients With A-fib and Cancer May Benefit From Visiting With a Cardiologist Early On

October 10, 2018

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

News Daily News

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

October 09, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.